Bioptic

Bioptic EBITDA Margin

The EBITDA Margin of Bioptic (6850.TWO) as of Nov 1, 2026 is 9.46 %. In the previous year, EBITDA Margin was 19.30 % — a change of -50.99% (lower).

EBITDA Margin

9.46 %

YoY

-50.99%

Last updated:

EBITDA Margin of Bioptic is 2024 9.46 % . EBITDA Margin of Bioptic was 2023 19.30 % . It decreases by -50.99% lower compared to the previous year.

The Bioptic EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-25.53 TWD
Jan 1, 2019
3.76 TWD
Jan 1, 2020
21.82 TWD
Jan 1, 2021
24.63 TWD
Jan 1, 2022
28.09 TWD
Jan 1, 2023
19.30 TWD
Jan 1, 2024
9.46 TWD
The Bioptic EBITDA Margin history
YEAREBITDA MarginYoY
9.46 %-50.99%
19.30 %-31.30%
28.09 %+14.06%
24.63 %+12.90%
21.82 %+480.15%
3.76 %-114.73%
-25.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioptic Stock analysis

What does Bioptic do? BiOptic Inc generates revenue through the sale of capillary electrophoresis instruments, including the Qsep100, Qsep1, and Qsep400 series, which are used for biomolecule separation and detection. The company also sells related consumables such as S1, S2, S3, F3 cassettes for DNA fragment analysis, R1 and NR1 cassettes for RNA detection, P2 cassettes for protein analysis, and Q series for quantitative detection. Additionally, BiOptic Inc offers reagents including polymerase chain reaction reagents, veterinary medicine-related reagents, human gene detection reagents, and food-related reagents. These products are primarily sold to customers in China, Hong Kong, and Taiwan, with the company focusing on the healthcare and research sectors. The firm's main customer segments include laboratories, hospitals, and research institutions that require advanced detection equipment and consumables for genetic and molecular analysis. BiOptic Inc's product portfolio targets both human and veterinary medical applications, as well as food safety testing, indicating a diversified market approach. The company's focus on high-precision instruments and specialized reagents positions it to serve clients needing reliable solutions for nucleic acid and protein analysis. BiOptic Inc's revenue streams are derived from direct sales of its instruments, cassettes, and reagents to end-users in the healthcare and research sectors. The company's products are designed for specific applications, such as DNA, RNA, and protein detection, which drives demand from specialized laboratories and medical facilities. By offering a comprehensive range of products, BiOptic Inc ensures that its customers can access all necessary tools for their molecular analysis needs within a single supplier. Bioptic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioptic stock

EBITDA Margin of Bioptic is 9.46 % in 2024.

EBITDA Margin of Bioptic changed from 19.30 % to 9.46 %, representing a -50.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Bioptic since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Bioptic with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bioptic

All Key Metrics — Bioptic